Skip to main content

Table 2 Characteristics (demographics and comorbidity) at the start of therapy with generic or brand-name statin

From: Treatment persistence and adherence and their consequences on patient outcomes of generic versus brand-name statins routinely used to treat high cholesterol levels in Spain: a retrospective cost-consequences analysis

Group

Brand-name

Generic

Total

p

Number of patients (%)

3007 (22.7%)

10,237 (77.3%)

13,244 (100%)

Sociodemographic characteristics

Average age (years)

61.4 (11.7)

61.2 (11.3)

61.3 (11.4)

0.501

Ranges:

    

 18–44 years

7.2%

7.7%

7.6%

 

 45–64 years

52.9%

51.9%

52.1%

 

 65–74 years

23.0%

25.9%

25.2%

 

  ≥ 75 years

16.8%

14.6%

15.1%

0.234

Sex (female)

52.7%

52.5%

52.6%

0.827

Pensioners

50.2%

51.6%

50.5%

0.191

General comorbidity

 Average diagnoses

6.6 (3.6)

6.5 (3.3)

6.5 (3.3)

0.502

 Charlson index

0.7 (1.0)

0.7 (1.0)

0.7 (1.0)

0.855

 Average RUB

2.9 (0.7)

3.0 (0.7)

3.0 (0.7)

0.527

 1 (very low comorbidity)

3.9%

3.4%

3.5%

 

 2 (low comorbidity)

15.4%

14.8%

14.9%

 

 3 (moderate comorbidity)

65.5%

66.7%

66.4%

 

 4 (high comorbidity)

13.2%

13.2%

13.2%

 

 5 (very high comorbidity)

2.1%

1.9%

1.9%

 

Associated comorbidities

 Hypertension

50.2%

51.6%

50.5%

0.191

 Diabetes mellitus

22.8%

23.0%

22.9%

0.786

 Obesity

19.4%

19.8%

19.5%

0.658

 Active smokers

24.0%

22.9%

23.7%

0.224

 Alcoholism

3.5%

4.2%

3.7%

0.064

 Ischemic heart disease

8.3%

9.4%

8.5%

0.057

 Cerebrovascular accident

11.0%

9.9%

10.8%

0.091

 Previous cardiovascular event

19.0%

18.3%

18.8%

0.382

 Organ failure

17.3%

17.7%

17.4%

0.675

 Dementia

2.4%

2.5%

2.5%

0.792

 Depressive syndrome

21.5%

21.4%

21.5%

0.182

 Malignant neoplasms

9.4%

9.0%

9.3%

0.537

  1. Values expressed as percentage or mean (standard deviation), p statistical significance between brand-name vs. generic, RUB resource utilization band